Solenne Chardigny

Today Sonio is reaching a new milestone towards improved access and quality of care for women and children worldwide: pending approval of the French Ministry of Economy, Sonio will join the Samsung Medison family! After 4 years of incredibly fast growth, building a unique product and above all things an exceptional team, this fantastic partnership will allow us to accelerate our roadmap, boost our commercial expansion globally and reaffirm our mission, while staying independent in our execution. I’m very excited about this new phase in Sonio’s life. Beyond the very strong technological and business rationale, this adventure is an opportunity to confirm our human and operational model at scale. I’m truly thankful to everyone who made this possible: 🙌 our incredibly driven team, who manages to combine excellence, humility, hard work and care - you so deserve this success! Get ready for this new ride together!! 🚀🚀 🙏 our investors, starting with our business angels, the first true believers Alain Decombe and all the funds after them Elaia, Bpifrance, OneRagtime, European Investment Bank (EIB), Cross-Border Impact Ventures - Annie Theriault thanks for being such a smart and committed partner, we are determined to pursue our mission and unfold our impact roadmap with your guidance🤰🏽 👩‍⚕️ our customers and clinical partners worldwide, who fed and validated our vision. We will continue to provide you with our device-agnostic AI-powered software solutions. We will keep our unprecedented clinical understanding of maternal and fetal medicine and ultrasound. We will preserve our agility and fast delivery to the benefit of physicians' workflow and patients outcomes Through this new success, I see the validation of an endeavor that goes beyond Sonio, the validation that there is a business model in healthtech and medical AI, that there is room for exceptional technology in health, that there is a huge women’s health market to address with deep unsolved pains, that the French Tech is unique, smart, fast and boiling with potential, that there is a way to become an entrepreneur after a career in the Corporate world (and vice-versa), that a woman, a mother, can and should shoot for the stars, it IS possible, you have to trust yourself!, that it’s ALL about the people you meet and trust along the way, in their diversity and humanity To my partners Remi Besson David Amouyal Deepak Prakash Dagmar Nuber THANK YOU! sooo excited to enter this new phase with you!!! Let’s keep building and having so much fun together!  To the early founders Yves Ville Julien Stirnemann Emmanuel Spaggiari Stéphanie Allassonniere Erwan LE PENNEC thanks for trusting me To our advisors Sacha Loiseau Yann Fleureau Laurent Merlino, thank you for your invaluable guidance, it made such a difference Special thanks to my husband Arnaud Dubois - my first sponsor and mentor Can’t wait to kick start after closing YangKyu (YK) Kim, Kyu Tae Yoo, Mathieu Apotheker! 🚀

705

115 commentaires

Looking forward to sharing my perspectives and hearing how others are approaching the global VC landscape at this session at #GRIC2024!

19

Super proud and excited to reveal the recent launch of Eos our newest start-up 🐣 within Kamet Ventures. Co-founded with Nicolas Gueugnier, Maxime Bouré and senior psychiatrist Lionel Gibert, Eos aims at helping people solve their alcohol dependancy. A massive and currently unsolved problem 😡: Alcohol is the First cause of hospitalisation in France - over 1,5m people are alcohol-dependent and the cost to Social Security is over 9b euros per annum (French only figures…) A breakthrough approach ✅ : Through a unique combination of digital/data, medical expertise and innovative pathway, Eos virtual clinic is re-inventing the way patients are taken care of along their (unfortunately) long journey to fully recover. And it is live now, treating 🩺 patients every day 😊 Eos is joining the long list of market-leading Digital Health companies created by Kamet Ventures over the last few years (just a few below): padoa digitising the Occupational and Prevention Health and already serving over 1/2 million companies and 6m french employees and still fast growing… HealthHero Qare the European leader in Telemedicine with over 6m annual digital consultations in France and the UK with a 96+% satisfaction rate and still fast growing… Birdie powering well over 20,000,000 elderly care visits annually in the UK and fast growing… Apricity Fertility the leading AI-driven Fertility clinic in the UK, helping thousands of women get a baby (and many more everyday…) Ibex Medical Analytics the AI-powered Digital pathology leader, deployed at over 50 Labs and hospitals globally, and changing the way Cancer is diagnosed all over the world… More news to be announced soon…🚀 Michaël Niddam Stephane Guinet Pierre de Mascarel Nicolas Bosc Léa Hubsch Lydia Katz Noelle Lewkowicz Paul Goodhind #VentureBuilder #StartUpStudio #DigitalHealth #AI #Telemedicine #Alcohol #Addiction #ElderlyCare #OccupationalHealth #Fertility #DigitalPathology

55

3 commentaires

🚀 Exciting News! 🚀 I had the incredible opportunity to be featured on BFM TV to discuss the innovative work we are doing in the field of digital pathology. 🎥🧬 In this 2-minute interview, I delve into how our cutting-edge technology is revolutionizing pathology by enhancing diagnostic accuracy and speeding up results for patients and healthcare providers alike. Check out the video below to learn more about our mission and how we are shaping the future of pathology.

84

4 commentaires

While I am not a fan of generative #AI use in PR and comms (people, I beg you, #ChatGPT texts are 100% recognizable as AI-generated from first glance), artificial intelligence has immense application potential in many other industries. No wonder there are hundreds of reporters in most respectable media focusing on this arm of IT alone. Governments, too, see what's coming and fuel this innovation. #Dubai, for instance, has announced it aims to generate 40% of its GDP with help of AI by 2031, and train 1 million prompt engineers in the process. Looking forward to seeing how this unfolds! https://lnkd.in/etA-ph8d

4

🙏Such a pleasure to be part of the conversation and exchange with European digital health experts at the European HealthTech Digital Conference in Luxembourg. Thanks to Luxinnovation GIE, Carole Bruckler, PhD and Jean-Philippe Arie for making this happen. Had the privilege to meet many superb people. 🤑My 10min message in a nutshell: while biotech and SaaS investing are well codified and value creation follows a well known framework all the way to exit, digital health isn’t mature enough to offer such levels of (relative) certainty. That explains the highly populated graveyard of dHealth startups and the relative investor mistrust in the sector. The silver lining: this sector is much more resilient than others once you’re on the growth path. With hard work and following basic business principles, it’s possible to find the recipe to success…😉

95

4 commentaires

🔍 France's Medtech sector is at a pivotal moment...In 2023, financial sponsor exits in French healthcare totaled just €141M compared to €1.3B in Germany and €8.1B in the US! Despite its rich history in medical innovation, the lack of local private equity investment is holding back promising companies. France currently accounts for 14% of the European medical device market but lags behind Germany’s 27%. The good news? There’s a backlog of mature French medtech firms generating revenues of €20M to €30M that are ready to scale up, but they need more local growth capital. Upcoming deals, such as Astorg’s stake in Echosens and Theravia’s exit pipeline, highlight the potential waiting to be unlocked. With the new European Commission expected to simplify regulations, the question remains: how can we harness PE support to ensure France's medtech sector thrives? Source : ION Analytics, Med Tech Europe #Healthcare #Medtech #Privateequity #Investments #France ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting senior industry experts, ex-payors, and KOLs with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. Join 16K+ followers by clicking my name + follow 🔔 Join 1.4K+ subs to my weekly newsletter 💌

19

One of the most fascinating developments I have seen in a long time. The future is here.

2

THE DAY AFTER Curiously, the CAC 40 (French stock exchange) is gaining a few points and the Euro is increasing with respect to the USD. Are the financial operators waiting for further developments or just relieved to see the far right failing to gain Matignon ? None of the different scenarios next to the election appear optimistic though. At this point, instability and confusion prevail. Let’s hope for a pro business perspective eventually.

2

[#NEXTHealthcare] Announcing the selected companies for Next Healthcare Booster 2024!🌟 Let us introduce the 9 companies moving on to the NEXT round and exploring the opportunity to develop their growth strategy in the North American market! 🚀   Sounduct, a medtech start-up specializing in audiology. The company's solution enable individuals who are deaf or hard of hearing to achieve high-performance hearing. The solution is based on non-invasive, non-destructive bone conduction technology integrated with AI. Olivier Gauthier   EzyGain, a medtech startup specializing in walking rehabilitation solutions, with a primary focus on revolutionizing gait training using an innovative pelvic weight-lifting system. Zineb AGOUMI, Thibault Faÿ, Justin Santamaria   Poly-Dtech, a biotech startup specializing in in-vitro diagnostics and life sciences. The company develops and produces high-performance fluorescent nanoparticles with unique characteristics to enhance biomarker detection. Joan Goetz   Apneal, a deeptech startup developing technologies that enable sleep examinations to be conducted at home using only the patient's smartphone. Guillaume Cathelain, Séverin Benizri   Quantiq.io, a start-up specialising in e-health, enabling measurement and diagnosis of every patient’s physiological constants thanks to AI algorithms. Fabien Kaplanas, Alain Habra, Célia Bouard   Somno Engineering, a medtech focusing on delivering tailored sleep management solutions in intensive care units to enhance patient recovery and reduce hospital stays. Maud de la belleissue, Xavier Drouot   INCEPTO, a startup specializing in digital health which offers a portfolio of selected AI applications to help interpret medical images via an integrated and secure platform. Charlotte Halb, Florence Moreau, Antoine Jomier, Mathieu Ficara   Persea, a biotech startup developing a MTI called BioTrojan, a game-changing treatment for solid cancers. Sophie de Ferrières   Lifebloom, , a medtech startup developing a unique medical device to empower individuals with reduced mobility to initiate and control their muscle activation, aiming to enhance stability, walking ability, and fall prevention. Damien Roche   🩺 Thank you to all companies that came forward, to our jury of experts and to our partners.   We're thrilled to kick off the NEXT 2024 journey with our sponsors FACCNE ⎮ French-American Chamber of Commerce, New England - Dentons - ORCOM | Expertise-comptable, audit, conseil - Air France - French Healthcare Ludmilla Potiron, Flavio Carratu, Louis Malatrait, Jerome Revole, Marie-Astrid Sevilla

128

7 commentaires

I was honored to join a panel yesterday, moderated by Jean Rognetta and Morgan Hunault-Berret, with fellow panelist Olivier Martret. The provocative topic on our agenda: “Have French VCs already lost against US VCs in GenAI?” It was the opportunity to share our thought at daphni, here are a few takeaways: 1) Fund size matters: While it's evident that apart from BPI, French VCs lack the critical size to play a significant role in foundational models funding rounds. However, reducing GenAI startups to 200M+ seed rounds is an oversimplification. We see a clear market segmentation between foundational models - that share caracteristics with infrastructure deals - and application layers. There are probably 4 deals in the last 18 months where French VC could not positionate. The issue of the size of French VC funds is an old debate, older than ChatGPT. 2) International mindset: French startups have been criticised a lot in the past for lacking ambition and international mindset. We have been expecting what’s happening right now for a while: it's time to celebrate. Most of the world's leading VC funds are now co-investing with us in France. 3) A Seed GenAI startup still have the problematic of a seed startup: Seed has always been dominated by local actors for sourcing reasons but also because the support you can bring is really ecosystem specific. 4) Co-investment: We're actually very enthusiastic about co-investing with US VCs, who bring added value and help French startups penetrate international markets. From an exit perspective, pursuing a US IPO remains the best scenario and requires to success in the US at some point. Having the right US VC in series A is a great support. 5) Building a Top Ecosystem: France is on track to establish itself as one of the world's top three ecosystems for GenAI, a feat not possible without foreign VCs. This isn't just national pride – it's a sentiment echoed by global investors who recognize the dynamic changes occurring within our borders and knock at the door to exchange about it. More to come soon! Thanks Louis Petitjean and Matthieu Bouhelier 

71

5 commentaires

🌍 Exciting times ahead for digital health in France! I had the honor of speaking at the roundtable on "Digital Medical Devices: Where do we stand in their assessment and what healthtech stakeholders need to know?" organized by the Agence de l'innovation en santé (Lise ALTER, Camille Schurtz 👏 ) at the "Next generation of clinical research" event in Lille. The discussion was rich with insights on the current landscape of research and the future of digital therapeutics in France, especially. Special thanks to our moderator, Line FARAH (Ministère de la Santé), and my fellow speakers: Jérôme Fabiano (EIT Health France), Corinne Collignon (Haute Autorité de Santé), Sarah Zohar (INSERM), Dr. Joris Giai (CHU Grenoble Alpes) and Louisa Stüwe (Ministère de la Santé). 💡 One of the key insights: YES, foreign clinical data can be used to apply for reimbursed of a digital medical device in France! Let's connect and explore opportunities together! 🚀

95

1 commentaire

🌟 #AI: Catherine Boule, Managing Partner at Karista, at the CHU X Healthtech Connexion Day 🌟 We are excited to announce that Catherine Boule, Managing Partner at Karista, will be joining the third edition of the CHU X Healthtech Connexion Day, organized by France Biotech and the Conference of General Directors of University Hospitals (CHU) on December 2nd in #Lille. During the 12:00-12:50 PM panel discussion, on the topic "AI in Healthcare Institutions: From Vision to Reality," Catherine and other experts will discuss how artificial intelligence is transforming healthcare, the management of health institutions, as well as the concrete benefits and ethical considerations involved in AI implementation in healthcare. This is a key opportunity to explore current and future challenges in health innovation and strengthen collaboration between hospital and industrial players to make a direct impact on patients and healthcare systems. Don’t miss this insightful discussion with leading experts! #Healthtech #HealthcareInnovation #AI #DigitalHealth #CHU #ArtificialIntelligence #HealthInnovation

9

At Beo Healthcare, we partner with multiple health professionals to ensure that #alix, our hybrid artificial intelligence, includes the right features and benefit for patients' quality of life. Alix is designed to target multiple diseases, including #cancer We want to thank MD, brain surgeons at CHU de Brest for sharing relevant research publications with us to allow the right developments of Alix, in particular to have a solution that is customized, specific to each individual Extracts from the Abstract ⤵️: " Fatigue is one of the most common adverse effects of cancer that might persist for years after treatment completion in otherwise healthy survivors. Cancer-related fatigue causes disruption in all aspects of quality of life and might be a risk factor of reduced survival. The prevalence and course of fatigue in patients with cancer have been well characterized and there is growing understanding of the underlying biological mechanisms. Inflammation seems to have a key role in fatigue before, during, and after cancer-treatment. However, there is a considerable variability in the presentation of cancer-related fatigue, much of which is not explained by disease-related or treatment-related characteristics" "... a variety of intervention approaches have shown beneficial effects in randomized controlled trials, including physical activity, psychosocial, mind–body, and pharmacological treatments..." #md #hospital #cancer #AI #AIforHealth #Healthcare #Europe #USA #futureofmedicine #physicalactivity #customizedmedecine #patientqualityoflife #brainsurgeon #fatigue #cancerrelatedfatigue Sophie Deniel Yannick GUILLODO Chloé Le Douarin Sullivan Gauville Lucas Morisseau Maxime B'chir Benoît Quero Jean-Luc DUFOUR Mathieu Champenois Yann Le DOUARIN Nature Research Custom Media UCLA MACMILLAN PUBLISHERS INTERNATIONAL LIMITED

8

Are French unicorns ready for their IPO? I'll say yes, and probably even a bit better than German startups! Let me tell you why. Most IPOs are driven by the CEO / CFO couple but there is a third important wheel to this constellation: the CMO! A big part of a successful IPO and then stock exchange valuation is communication. It's all about trust, baby! And trust is built through communication & thought leadership. French startups are often very strong in being transparent and proactive in their communications. So this is a solid basis to work on. Here are my learnings from working on KATEK GROUP's IPO: ‣ It's not all about the press: Yes, mandatory investor relations (IR) news have to be communicated through the press. By going further and also using your company's owned channels you show even more transparency to your stakeholders. Communicating on LinkedIn will enable dialog with your investors. ‣ IR does not need to be boring: Financial reports might not sound as sexy as the next big brand campaign, but it can be. Use videos to explain the numbers further, plan live Q&A sessions with the CEO. Be creative and stay true to your brand's values. ‣ It's about the people: The stock exchange market is a numbers and money world. By involving your C-level in the communication you will be able to build up a stronger trust in your company. In people we trust! Here think about news hijacking to position your C-level as the experts they are, do video interviews or quote statements. You can read more about KATEK's IPO and strategic communication here: https://lnkd.in/dFYscP3k #IPO #ListedInFrankfurt #FrenchTech #StartupCommunication

3

#Weekendread “I have always been a person who loves to ask questions. I'm very curious, which I believe is an important quality when working in foresight.” 🔎 Agathe Acchiardo is a healthcare foresight consultant and Vision Health Pioneers Incubator coach. 💊 Working for 9 years in the #pharma industry, Agathe acquired a deep understanding of diverse healthcare systems and cultural differences across countries regarding health management. This knowledge informs her work with her agency Think Next, where she works with large healthcare companies on their #innovation agenda to help them become more future-oriented. 👩‍⚕️ She also supports startup teams like ours. “I love working with startups because they have a certain vision about the #future of health. They bring optimism and a can-do approach that you don’t always find among corporate clients.”  However, enthusiasm and passion are not enough to succeed. "They need to get a sense of the broader context; the future of healthcare and how their solution might fit in – not only for the next funding round, but ideally in the next 3, 5, 7, 10 years." Agathe built her career around supporting organizations to become future-fit and stay relevant. Learn more about why foresight matters for your business. Discover a useful tool to get you started. Read the interview 👉 https://lnkd.in/da3Gqcnc

9

Vital signs with your phone! Is it the end of traditional monitors and IoMT? This innovation opens up a new horizon of possibilities for patient care...

5